| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 73 | 141 | ||
| General and administrative expenses | 178 | 174 | ||
| Operating loss | -251 | -315 | ||
| Total financial expense | -4 | -7 | ||
| Net loss | -255 | -322 | ||
| Basic net loss per share (in dollars per share) | 0.01 | 0.02 | ||
| Diluted net loss per share (in dollars per share) | 0.01 | 0.02 | ||
| Weighted average number of shares of common stock used in computing basic net loss per share (in shares) | 19,626,418 | 19,626,418 | ||
| Weighted average number of shares of common stock used in computing diluted net loss per share (in shares) | 19,626,418 | 19,626,418 | ||
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)